Biologics CDMOs double down on Europe as orders surge
The gist
Biologics CDMOs are making Europe their operational center stage as surging demand turns contingency plans into billion-dollar realities.
What to know
- WuXi Biologics is betting big on Europe by running its Dundalk, Ireland hub at 54,000L capacity with EMA-approved production and a new HPRA GMP license.
- Samsung BioLogics just clinched a $262 million European CMO deal, boosting its total orders to a record $21.9 billion and capacity to a jaw-dropping 845,000 liters.
- This regional expansion is driven by real, booked orders—not just future promises—proving Europe's biologics boom is the real deal.
Europe Becomes Core Strategy
WuXi Biologics is shifting from backup plans to a full-fledged European operating model, integrating dual sourcing and regional supply resilience across its Irish and Spanish hubs.
What makes this moment consequential is that European diversification is no longer framed as contingency planning but as an operating model. At CPHI Milan 2026 (Oct. 9, 2026), WuXi Biologics said it “brings these capabilities together through its integrated CRDMO platform and strategically positioned operations in Europe,” explicitly tying that setup to “resilient regional supply,” while its Global Dual Sourcing model aligns quality, analytics and technology transfer across sites so customers can choose alternative manufacturing pathways based on program, market and supply needs rather than rely on a single location.
That strategy is being translated into concrete European capacity and execution. According to PR Newswire UK, Dundalk, Ireland is “WuXi Biologics' established commercial manufacturing hub in Europe,” operating under an “HPRA GMP manufacturing license,” supporting “EMA-approved commercial products,” and having “54,000 L of drug-substance manufacturing capacity across perfusion and fed-batch platforms”; the company adds that “In 2026, the site secured multiple new large-scale manufacturing projects and initiated the associated technology transfers,” while 53Biologics’ Spain lyophilization expansion shows the same targeted, facility-level investment logic extending into regional fill-finish capability.
Orders Outpace Announcements
Thermo Fisher and Samsung BioLogics are seeing real-time surges in European contracts and manufacturing throughput, with Samsung’s record-breaking deals backed by proven capacity and regulatory wins.
The strongest evidence that this build-out matters commercially is that demand is already showing up in orders and throughput, not just in announced capacity. In Q&A on its Q2 2026 results, Thermo Fisher said it “saw none of that strong growth” concerns—specifically “no delays”—while highlighting bioproduction growth, and management added there is “roughly a six month lag between bookings and revenue,” so “today’s strong authorizations are a good forward signal,” indicating facilities are being pulled by real programs rather than standing by for hypothetical future work.
Samsung BioLogics offers the clearest scale proof: 아시아경제 reported it “lands $262 M European CMO deal,” a win that “push[es] total orders to $21.9 B,” while a later profile said orders secured since John Rim became CEO in December 2020 total nearly 20 trillion won, with cumulative contract wins of 19.5883 trillion won since 2021. That order momentum sits on measurable manufacturing heft—its March acquisition of GSK’s 60,000-liter Rockville plant lifted total capacity to 845,000 liters—and on execution credibility, with a 99% batch success rate and 464 cumulative global regulatory approvals.
